Related Experiment Videos
Dose proportionality of cisatracurium
V D Schmith1, J Fiedler-Kelly, L Phillips
1Glaxo Wellcome, Inc., Research Triangle Park, North Carolina 27709, USA.
Journal of Clinical Pharmacology
|July 1, 1997
Summary
The pharmacokinetics of cisatracurium are independent of dose, as demonstrated by a population pharmacokinetic approach. This finding supports the drug
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Drug Metabolism
Background:
- Cisatracurium is a neuromuscular blocking agent used in anesthesia.
- Understanding cisatracurium pharmacokinetics is crucial for safe and effective dosing.
- Hofmann elimination is a primary metabolic pathway for cisatracurium, independent of enzymatic activity.
Purpose of the Study:
- To assess the dose proportionality of cisatracurium pharmacokinetics.
- To evaluate cisatracurium's pharmacokinetic profile across a range of clinical doses.
Main Methods:
- Population pharmacokinetic analysis using nonlinear mixed-effects modeling (NONMEM).
- Pooled sparse and full plasma concentration-time data from 169 patients.
- Dichotomous parameterization and linear modeling to assess dose proportionality.
Main Results:
- Cisatracurium pharmacokinetics were found to be independent of dose within the tested range (0.1-0.4 mg/kg).
- The results align with the known mechanism of Hofmann elimination, which is pH and temperature-dependent, not dose-dependent.
Conclusions:
- The dose-independent pharmacokinetics of cisatracurium are confirmed.
- This supports consistent drug exposure regardless of dose within the studied range, simplifying clinical use.